Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical

Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Rong, Yan, Youyou, Zeng, Xiaokang, Lin, Nengming, Tan, Biqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508996/
https://www.ncbi.nlm.nih.gov/pubmed/36164415
http://dx.doi.org/10.2147/DDDT.S377697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508996/
https://www.ncbi.nlm.nih.gov/pubmed/36164415
http://dx.doi.org/10.2147/DDDT.S377697

Ejemplares similares